CDX-011: Phase II data

In 26 evaluable patients from the Phase II portion of a Phase I/II trial, 1.88 mg/kg IV CDX-011 met the primary endpoint, which required >=5 of 25 (20%) patients in

Read the full 309 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE